Business
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 11:00 a.m. PT.
About this update from Calcimedica, Inc.
[{"type":"text","content":"LA JOLLA, Calif., April 1, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 11:00 a.m. PT.","length":525,"tagName":"p"},{"type":"image","alt":"CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)","displaySize":"","headline":null,"caption":"CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":78,"url":"https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OrsqdcERGNiUdevuO33D2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae","width":400,"height":78}},"href":"https://mma.prnewswire.com/media/685404/calcimedica_v3.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.","length":255,"tagName":"p"},{"type":"text","content":"About CalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammat...